Kilambi News
Saturday, November 21, 2026

Archive

Every story, newest first.

Saturday, November 7, 2026

Rates

Ueda traces Japan surplus shift in IMF Camdessus lecture

Bank of Japan Governor Kazuo Ueda told the IMF's Camdessus lecture on Friday that Japan's current account surplus, still 2 to 4 percent of GDP, is now carried by overseas investment income above 6 percent of GDP rather than by exports, and offered no new signal on monetary policy.

Rates

Rates also notable: Czech premier attacks hike, Ueno payouts widen

Czech Prime Minister Andrej Babis was reported to have called the central bank's latest rate increase scandalous, Paraguay's Ueno Bank depositors began receiving guarantee transfers, and the Bank of Canada's summary of deliberations is due on November 10.

Rates

Fed speakers split after payrolls as Daly backs tightening

San Francisco Fed President Mary Daly said on Friday that further rate increases are likely to be needed, hours after October payrolls rose 165,000, while New York Fed President John Williams urged gathering more information and the White House argued the jobs report is no reason to hike.

Life Sciences

Satellos switches Duchenne trial endpoint to MRI measure

Following FDA feedback, Satellos Bioscience has made change in MRI measured muscle fat fraction the primary efficacy endpoint of its Phase 2 BASECAMP trial of forazapadin in 53 boys with Duchenne muscular dystrophy.

Life Sciences

Sarepta closes enrollment in Elevidys confirmatory trial ENVISION

Sarepta Therapeutics will not resume enrollment in ENVISION, the Phase 3 confirmatory trial for its Duchenne gene therapy Elevidys, which enrolled 90 participants and has been on global hold for more than a year.

Life Sciences

Moderna swings to profit and raises revenue outlook

Moderna reported third quarter net income of 162 million dollars on revenue of 1.31 billion dollars, up 29 percent year on year, against a net loss of 200 million dollars a year earlier.

Life Sciences

Lilly puts Zepbound and Foundayo on Hims platform

Eli Lilly will sell its obesity medicines Zepbound and Foundayo directly through the Hims and Hers telehealth platform at self pay prices starting at 299 dollars and 149 dollars a month.

Life Sciences

Immunocore combination shows early activity in uveal melanoma

In a Phase 1/2 study, Immunocore's brenetafusp combined with Kimmtrak produced a 29 percent response rate and an estimated 70 percent two year survival rate in 17 evaluable first line patients with metastatic uveal melanoma.

Life Sciences

Four states sue to block Medicaid work requirements

Oregon, Minnesota, New Mexico and Washington sued the Trump administration on November 5 to block Medicaid work requirements that take effect on January 1, 2027, arguing the conditions exceed Congress's spending power.

Life Sciences

Also notable in life sciences on November 7

Alnylam's chief commercial officer is leaving amid Amvuttra sales concerns, ANI Pharmaceuticals offered 560 million dollars for Sweden's Egetis Therapeutics, and Ultragenyx will cut 1,000 jobs after its Angelman gene therapy failed.